Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pathogenic autoantibodies are antibodies produced by the immune system that mistakenly target and react with an individual's own tissues or organs, leading to inflammation, tissue injury, and the development of autoimmune diseases. They are typically high-affinity IgG (or sometimes IgA) molecules that have undergone somatic hypermutation and class-switch recombination. They contribute to disease through mechanisms such as loss of self-tolerance, molecular mimicry, epitope spreading, and altered antigen presentation. Targeting these antibodies is a major strategy for treating severe autoimmune conditions.
B-cell/plasma cell depletion, antibody neutralization, immunosuppression
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pathogenic Autoantibodies.